HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac condition detection, was featured in coverage of the 38th Annual ROTH Conference. The company is developing the first cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable use, enabling physicians to gather actionable heart intelligence wherever a patient is located.
The HeartBeam System's 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. The company's 3D ECG technology had previously received FDA clearance for arrhythmia assessment in December 2024. According to the company's Cleared Indications for Use available at https://www.heartbeam.com/indications, this technology allows physicians to identify cardiac health trends and acute conditions outside traditional medical facilities, potentially directing patients to appropriate care more efficiently. HeartBeam holds over 20 issued patents related to this technology enablement.
The technology's implications for cardiac health management are significant, as it could redefine how cardiac conditions are monitored and detected. By enabling portable 12-lead ECG collection, the system may facilitate earlier intervention for cardiac events and improve remote patient monitoring capabilities. This development comes at a time when telehealth and remote medical technologies are increasingly important for healthcare delivery.
Coverage of the conference was provided by IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company that created a custom-built portal for the investment community to access information about participating companies. IBN's coverage included summaries of each company at the conference, along with access to market research tools and website links. The company has provided real-time coverage for numerous global events and conferences for more than a decade through various brands, social media accounts, and investment newsletters.
IBN's syndication partners extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. Additional information about IBN's services and coverage can be found at https://www.InvestorBrandNetwork.com. The full terms of use and disclaimers applicable to all content provided by IBN are available at http://IBN.fm/Disclaimer.
InvestorWire, a specialized communications platform within IBN's Dynamic Brand Portfolio, also contributed to the conference coverage. InvestorWire focuses on wire-grade press release syndication for companies and the investment community, offering article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. More information about InvestorWire's services is available at https://www.InvestorWire.com, with full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
The inclusion of HeartBeam in this financial conference coverage highlights the growing interest in medical technology innovations that address remote healthcare needs. As cardiac conditions remain a leading cause of mortality worldwide, technologies that improve detection and monitoring outside clinical settings could have substantial impact on patient outcomes and healthcare system efficiency.
